/

KMDA

Kamada Ltd.Open

7.65−0.19 −2.42%USD

NasdaqGS · as of Oct 13, 14:41 ET · 15m delay

Open

7.87

Prev close

7.84

Day range

7.597.87

52-week range

6.559.35

Volume

66.86K0.56×

Mkt cap

441.48M

P/E ttm

20.13

Fwd P/E

13.27

EPS ttm

0.3800

Div yield

2.16%

Earnings

Aug 12, 2026

From 52w high

−18.18%

Price Chart

Yahoo Finance · delayed

KMDAOct 13, 2026O 7.87H 7.87L 7.59C 7.65−0.19 (−2.42%)Vol 66.86K

SMA 508.09
SMA 2008.00

1Y change +12.50% since Oct 10, 2025 close540 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

KMDA Kamada Ltd. · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: −5.67%
1 month: −3.41%
3 months: +5.23%
6 months: −9.14%
Year to date: +8.36%
1 year: +11.19%

Valuation & ownership

Market cap: 441.48M
Enterprise value: 395.51M
P/E (ttm): 20.13
Forward P/E: 13.27
PEG ratio: 0.60
Price / book: 1.64
Price / sales (ttm): 2.30
EV / EBITDA: 9.53
EPS (ttm): 0.3800
EPS (forward): 0.5767
Beta (5y monthly): 0.13
Dividend yield: 2.16%
Payout ratio: 65.79%
Shares outstanding: 57.71M
Float: 33.18M
Short % of float: 0.67%
Short ratio (days): 1.46
Held by insiders: 6.99%
Held by institutions: 49.17%
Avg volume (3m): 119.55K
50-day average: 8.08
200-day average: 8.00
52-week change: +11.19%
S&P 500 52-week: +17.50%

Technicals (daily)

RSI (14): 38.8
vs 50-day SMA: −5.46%
vs 200-day SMA: −4.41%
50 / 200-day trend: ▲ 50 above 200
MACD vs signal: ▼ below
ATR (14) % of price: 3.45%
Realised vol (20d, ann.): 40.0%
From 52-week high: −18.18%
From 52-week low: +16.79%

ANR

Analyst Consensus

4 analysts

Consensus

Strong buy

1.00 on a 1 (strong buy) – 5 (sell) scale

Mean target

13.50

+76.47% implied

Low 11.00Median 14.00High 15.00

Recommendation trend

Now3 / 0 / 0
1m ago3 / 0 / 0
2m ago

DES

About Kamada Ltd.

Yahoo Finance profile

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its products include KAMRAB/KEDRAB indicated as prophylaxis of rabies; CYTOGAM for prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; and Echis coloratus and Vipera palaestinae Antiserum to treat snake bite. The company also distributes biopharmaceutical products in Israel, including BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; TRIMBOW for chronic obstructive pulmonary disease; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN and RUPAFIN ORAL SOLUTION for allergic rhinitis and Urticaria; SINTREDIUS for rheumatoid arthritis, systemic lupus erythematosus, and mild-moderate juvenile dermatomyositis; IVIG for various immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for prevention of hepatitis B; MEGALOTECT CP for CMV virus; RUCONEST for angioedema attack; HEPARIN SODIUM INJECTION for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN and ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. In addition, it distributes COAGADEX to treat hereditary factor X deficiency; IXIARO for Japanese encephalitis; VIVOTIF for salmonella typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis; RYPLAZIM for hypoplasminogenemia; ELIGARD for prostate cancer; and BEVACIZUMAB KAMADA for various cancers. The company was incorporated in 1990 and is headquartered in Rehovot, Israel.

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Employees: 462

SEAS

Seasonality · KMDA

2013–2026 · monthly returns

Strongest month Jan +3.23%Weakest month May −4.08%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	17.8	4.6	-4.1	-2.4	-4.1	-6.0	-2.7	15.3	2.8	-9.6			+8.4%
2025	10.5	2.4	-4.1	-2.1	5.9	13.1	-4.6	-6.4	0.3	-0.3	-3.2	5.4	+15.9%
2024	-6.4	9.9	-11.0	-7.0	1.0	-5.9	13.9	1.8	-6.6	6.9	2.6	3.4	−0.5%
2023	16.7	-7.7	7.4	0.4	3.6	9.3	-6.6	16.6	-7.1	-20.8	11.8	29.4	+52.6%
2022	-8.1	-8.3	-0.5	-2.7	-16.0	0.0	13.7	-2.7	-9.6	0.0	4.2	-14.7	−39.1%
2021	-0.2	-5.1	0.8	-2.6	-2.7	-0.9	-6.5	-1.1	-1.5	7.7	9.1	5.6	+1.5%
2020	-4.8	-10.6	0.3	28.6	4.7	-1.1	14.2	12.0	-15.7	-14.5	-5.2	-4.4	−5.1%
2019	5.0	17.5	-7.1	0.2	-5.1	1.3	2.7	-1.1	-8.6	1.9	42.1	-8.1	+36.6%
2018	14.7	-3.7	-12.4	3.3	6.3	3.0	10.6	3.5	4.2	-14.5	-1.5	-4.2	+5.3%
2017	14.5	11.4	-2.2	5.1	-1.4	-14.9	-20.8	-5.3	6.7	4.2	-6.4	1.5	−12.8%
2016	-10.8	-4.3	8.2	2.6	-6.9	0.3	7.9	21.7	6.4	12.1	-3.5	-1.8	+31.3%
2015	6.1	11.9	-2.0	-2.3	5.6	-16.2	0.8	-9.6	-1.7	17.0	5.8	-1.9	+9.2%
2014	1.5	14.8	-16.4	-1.3	-44.0	-11.0	-2.4	-1.3	-35.1	-7.2	-22.9	19.1	−74.4%
2013						10.5	13.2	1.0	20.0	-6.1	5.4	-1.8	+47.2%

INSD

Insider Activity · KMDA

Market-wide insider buying →Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

119K shares

Sells, 6 months

200K shares

Net shares

−81K

Net change in insider shares

−2.00%

Date	Insider	Transaction	Shares	Value
Sep 13, 2026	Livneh NirGeneral Counsel	Conversion of Exercise of derivative security at price 5.37 per share.	10K	$53.70K
Sep 13, 2026	Brenner YaelOfficer	Conversion of Exercise of derivative security at price 5.93 per share.	27K	$159.90K
Sep 13, 2026	Tsur DavidDirector	Sale at price 8.18 per share.	22.8K	$186.72K
Sep 8, 2026	Tsur DavidDirector	Sale at price 8.26 - 8.28 per share.	177.2K	$1.46M
Sep 1, 2026	Tsur DavidDirector	Conversion of Exercise of derivative security at price 5.94 - 7.36 per share.	49K	$328.69K
Sep 1, 2026	Brenner YaelOfficer	Conversion of Exercise of derivative security at price 5.94 per share.	3K	$18.03K
Aug 25, 2026	Brenner YaelOfficer	Conversion of Exercise of derivative security at price 6.25 per share.	30K	$187.50K

13F

Investors Holding KMDA

latest 13F filings of 29 followed managers

Investors holding KMDA
Investor	Value	Of portfolio	Shares	Change	Quarter
Renaissance Technologies	$5.4M	0.01%	742.42K	−2.7%	Q2 2026
ARK Investment Management · Cathie Wood	$1.9M	0.01%	263.30K	−2.3%	Q2 2026

From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors

KMDA

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

KMDA

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Kamada Ltd.

Seasonality · KMDA

Insider Activity · KMDA

Congress Trades · KMDA

Investors Holding KMDA

Investors Holding KMDA

Congress Trades · KMDA

Insider Activity · KMDA

Seasonality · KMDA

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Kamada Ltd.

Financial Snapshot

Earnings & Dividends

News